Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

Hims & Hers Health Inc. Class A

If you only glance at the share price, you might think the Hims & Hers Health ($HIMS) story has lost its spark. The stock has declined by more than...

Hims & Hers (HIMS) Investors Keep the Faith as Stock Slides 15%

Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite the consumer telehealth company launching a new “affordable” healthcare...

Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform

In a report released on November 4, Craig Hettenbach from Morgan Stanley maintained a Hold rating on Hims & Hers Health, with a price target of $40...

Morgan Stanley Sticks to Their Hold Rating for Hims & Hers Health (HIMS)

Hims & Hers Health ($HIMS) stock has been a wild ride lately, as investors struggle to decide whether it’s the future of consumer health or just a ...

Hims & Hers Health (HIMS) Looks to Turn GLP-1 Hype Into Health Empire

Hims & Hers Health, Inc. (($HIMS)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Hims & ...

Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report), BioNTech SE (BNTX – ...

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS), BioNTech SE (BNTX) and Precision BioSciences (DTIL)

In a report released today, Justin Patterson from KeyBanc maintained a Hold rating on Hims & Hers Health. The company’s shares closed yesterday at ...

KeyBanc Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to o...

Hims & Hers Stock (HIMS) Pops on Talks to Offer Novo Nordisk’s Wegovy

HIMS Earnings: Hims & Hers Health Reports Mixed Financial Results

Telehealth platform Hims & Hers Health ($HIMS) is scheduled to announce its third-quarter earnings on Monday, November 3, and the options market is...

Hims & Hers Health (HIMS) Q3 Earnings on November 3. Option Traders Expect a 14.56% Move

Hims & Hers ($HIMS) stock is drawing attention ahead of its Q3 earnings as the company expands into the booming weight-loss drug market. Yesterday,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HIMS	$34.71	+3.24%	18.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HIMS	$34.71	+3.2%	18.78M
3
4
5
6

HIMS

HIMS

Get Hims & Hers Health Inc. Class A Data in Excel

Get Hims & Hers Health Inc. Class A Data in Excel